Uncategorized Archives - Page 9 of 134

WednesdayJul 24, 2024 9:00 am

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Age-related macular degeneration is a disease significantly impacting the quality of life, making it difficult for individuals to perform everyday activities such as reading, driving, and recognizing faces InMed is currently developing a pipeline of drugs, like INM-089, to treat diseases with a high unmet medical need Delivers improved retinal pigment epithelium integrity, neuroprotection and photoreceptor improvement in in vivo preclinical disease model Age-related macular degeneration (“AMD”) is a prevalent eye condition that primarily affects older adults, leading to vision loss in the central part of the retina, known as the macula. This disease significantly impacts the quality of life, making it…

TuesdayJul 23, 2024 9:45 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

The new executive team includes Mark White, Alexander Morin, Hilda Maibach, and Blake Jensen These additions are pivotal as the company makes strides toward bringing flagship drug candidate buntanetap closer to New Drug Application (“NDA”) status and to market Annovis Bio (NYSE: ANVS), a pioneering late-stage clinical drug platform company focusing on transformative therapies for neurodegenerative disorders such as Alzheimer’s Disease (“AD”) and Parkinson’s Disease (“PD”), is thrilled to welcome four seasoned professionals to its executive team. Maria Maccecchini, Ph.D., Founder, President, and CEO of Annovis Bio, said the company was delighted to have this strong group of individuals join…

TuesdayJul 23, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

CNM-Au8(R) works by improving cellular energy production and utilization, which is crucial for maintaining neuronal health Clene has conducted several clinical trials to evaluate the safety and efficacy of CNM-Au8 in neurodegenerative diseases, including amyotrophic lateral sclerosis (“ALS”) The global ALS treatment market is expected to grow significantly, driven by the increasing prevalence of the disease among the aging population Clene has submitted a briefing book to the FDA to seek feedback on a potential pathway for accelerated approval for CNM-Au8 to treat ALS Clene (NASDAQ: CLNN), a biopharmaceutical company, is at the forefront of transforming the treatment of neurodegenerative…

FridayJul 19, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12% of Parkinson’s Disease patients showed cognitive decline, buntanetap not only halted this decline but also led to improvements Annovis held a webcast to go over the results in more depth, which is available for replay on the company’s website Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s…

ThursdayJul 18, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage…

WednesdayJul 17, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is…

MondayJul 08, 2024 12:00 pm

Astiva Health Inc. Leading the Way as Record Number of People Choose Medicare Advantage Plans

For the first time in Medicare’s history, more than half of all eligible people with Medicare are enrolled in private Medicare Advantage plans Enrollment in Medicare Advantage programs is projected to grow from 54% of the eligible population in 2024 to 60% by the end of the decade Astiva Health has developed one of the most diverse networks in Southern California and offers a selection of benefits tailored to the specialized needs of its members According to a recent KFF report, a record number of people enrolled in private Medicare Advantage plans last year (https://ibn.fm/YEpRJ). That trend bodes well for Astiva Health,…

FridayJul 05, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023 CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment. The data was presented by Dr. Karen Ho, Clene’s Vice President…

FridayJun 28, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

Buntanetap is designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43 The study demonstrated significant efficacy and safety for buntanetap in a subgroup of early Alzheimer’s patients in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a recognized genetic factor linked to Alzheimer’s Annovis Bio has been selected to present detailed data from its Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 June is Alzheimer’s & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer’s disease and other forms of dementia, as well as the importance of…

WednesdayJun 26, 2024 2:00 pm

BioMedNewsBreaks – Tivic Health(R) Systems (NASDAQ: TIVC) Names New Board Member

Tivic Health(R) Systems (NASDAQ: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of Christina Valauri to the company’s board of directors, effective July 1, 2024. “Over the past year, as an advisor to our Board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders,” TIVC Chair of the Board Sheryle Bolton…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

InMed Pharmaceuticals Inc.’s (NASDAQ: INM) INM-089, a Promising Treatment for Age-Related Macular Degeneration

Annovis Bio Inc. (NYSE: ANVS) Announces New Executive Team Members

Clene Inc. (NASDAQ: CLNN) Presents Updates on CNM-Au8(R) at Emerging Growth Conference 73 – Biotech Feature

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Astiva Health Inc. Leading the Way as Record Number of People Choose Medicare Advantage Plans

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

BioMedNewsBreaks – Tivic Health(R) Systems (NASDAQ: TIVC) Names New Board Member

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search